Home Healthcare Biotechnology Antibodies Market

Antibodies Market Size, Share & Trends Analysis Report By Type (Monoclonal Antibodies, Polyclonal Antibodies, Antibody Drug Conjugates), By Application (Oncology, Autoimmune Diseases, Infectious Diseases, Neurological Diseases, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Mitiksha Koul | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Antibodies Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Monoclonal Antibodies
    2. Polyclonal Antibodies
    3. Antibody Drug Conjugates
  2. Antibodies Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Oncology
    2. Autoimmune Diseases
    3. Infectious Diseases
    4. Neurological Diseases
    5. Others
  3. Regional Antibodies Market
    1. North America
      1. North America Antibodies Market By Type 2022-2034 (USD MILLION/ Units)
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
      2. North America Antibodies Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune Diseases
        3. Infectious Diseases
        4. Neurological Diseases
        5. Others
      3. U.S.
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      4. Canada
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
    2. Europe
      1. Europe Antibodies Market By Type 2022-2034 (USD MILLION/ Units)
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
      2. Europe Antibodies Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune Diseases
        3. Infectious Diseases
        4. Neurological Diseases
        5. Others
      3. U.K.
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      4. Germany
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      5. France
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      6. Spain
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      7. Italy
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      8. Russia
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      9. Nordic
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      10. Benelux
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      11. Rest of Europe
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
    3. APAC
      1. APAC Antibodies Market By Type 2022-2034 (USD MILLION/ Units)
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
      2. APAC Antibodies Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune Diseases
        3. Infectious Diseases
        4. Neurological Diseases
        5. Others
      3. China
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      4. Korea
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      5. Japan
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      6. India
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      7. Australia
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      8. Taiwan
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      9. South East Asia
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      10. Rest of Asia-Pacific
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
    4. Middle East and Africa
      1. Middle East and Africa Antibodies Market By Type 2022-2034 (USD MILLION/ Units)
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
      2. Middle East and Africa Antibodies Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune Diseases
        3. Infectious Diseases
        4. Neurological Diseases
        5. Others
      3. UAE
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      4. Turkey
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      5. Saudi Arabia
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      6. South Africa
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      7. Egypt
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      8. Nigeria
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      9. Rest of MEA
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
    5. LATAM
      1. LATAM Antibodies Market By Type 2022-2034 (USD MILLION/ Units)
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
      2. LATAM Antibodies Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune Diseases
        3. Infectious Diseases
        4. Neurological Diseases
        5. Others
      3. Brazil
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      4. Mexico
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      5. Argentina
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      6. Chile
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      7. Colombia
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
      8. Rest of LATAM
        1. Monoclonal Antibodies
        2. Polyclonal Antibodies
        3. Antibody Drug Conjugates
        4. Oncology
        5. Autoimmune Diseases
        6. Infectious Diseases
        7. Neurological Diseases
        8. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.